Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company.It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products.The company was founded on October 1, 2013 and is... 
Sector
Pharmaceuticals
Calendar
02/17Earnings Release
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Financials ($)
Sales 2014 12 652 M
EBIT 2014 3 644 M
Net income 2014 847 M
Debt 2014 14 020 M
Yield 2014 -
Sales 2015 15 569 M
EBIT 2015 5 397 M
Net income 2015 3 441 M
Debt 2015 8 735 M
Yield 2015 -
PER 2014 -
PER 2015 18,01
EV / Sales 2014 6,57x
EV / Sales 2015 5,00x
Capitalization 69 154 M
More Financials
Latest news on ACTAVIS INC
2d agoDJU.S. HOT STOCKS : Hot Stocks to Watch
2d agoDJActavis CEO to Remain After Allergan Merger
3d agoDJBrent Saunders faces challenge of running combined Actavis-Allergan
12/10 ACTAVIS : Launches Generic Version of Celebrex®
12/09DJMerck Reaffirms Commitment to Cubist Deal Despite Patent Ruling -- Update
12/09 Exclusive - Valeant to drop deal-making in near term to cut debt, boost stock
12/09DJMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update
12/09DJMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update
More news
Sector news
6h ago Roche to pay up to $489 million for next-generation antibody developer
7h ago MERCK : buys Swiss biotech with promising cancer drug
9h ago France fines household product firms 951 million euros for price fixing
More sector news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF